Sanara MedTech Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Sanara MedTech Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $15.59M | Mar 30, 2021 |
| FY2020 | Dec 31, 2019 | $11.77M | Mar 30, 2021 |
| FY2018 | Dec 31, 2018 | $5.84M | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | $6.30M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $5.51M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $3.37M | Apr 4, 2017 |
| FY2015 | Dec 31, 2014 | $2.63M | Apr 14, 2016 |
| FY2014 | Dec 31, 2013 | $1.73M | May 1, 2015 |
| FY2013 | Dec 31, 2012 | $1.17M | Apr 30, 2014 |
| FY2012 | Dec 31, 2011 | $2.21M | Apr 12, 2013 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.12M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $86.67M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $64.99M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $45.84M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $24.14M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $15.59M | Mar 31, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.60M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $78.53M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $57.14M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $39.48M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $21.83M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $13.97M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $10.56M | Mar 30, 2021 |
| FY2018 | Dec 31, 2018 | $5.33M | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | $5.50M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $4.56M | Mar 29, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($37.56M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($9.66M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($4.30M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($7.94M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($7.92M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($4.45M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.81M) | Mar 30, 2021 |
| FY2018 | Dec 31, 2018 | ($600.6K) | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | $331.3K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($415.7K) | Mar 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.30M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.26M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($4.22M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($12.52M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($7.38M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($5.03M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.74M) | Mar 30, 2021 |
| FY2018 | Dec 31, 2018 | ($501.9K) | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | $120.4K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($272.1K) | Mar 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.07M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $2.83M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $4.13M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $3.37M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $558.7K | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $40.2K | Mar 31, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $78.72M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $71.67M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $56.99M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $45.98M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $28.05M | Mar 20, 2023 |
| FY2011 | Dec 31, 2011 | $2.75M | May 1, 2012 |
| FY2011 | Dec 31, 2010 | $2.34M | May 1, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.79M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($23.8K) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($3.25M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($5.55M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($4.81M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($4.03M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.17M) | Mar 30, 2021 |
| FY2018 | Dec 31, 2018 | $277.1K | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | ($139.9K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $409.2K | Mar 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.63M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $205.8K | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $265.2K | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $147.0K | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $171.9K | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $544.4K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $182.8K | Mar 30, 2021 |
| FY2018 | Dec 31, 2018 | $8.5K | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | $43.9K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $3.0K | Mar 29, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.94M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $88.09M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $73.87M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $61.04M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $36.40M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $9.83M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $11.12M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.71M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $2.22M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $2.17M | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.01M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $49.18M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $29.28M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $19.32M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $6.24M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $3.99M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $4.72M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.12M | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $2.12M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $2.59M | Mar 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.94M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $39.40M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $44.83M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $41.83M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $30.64M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $6.15M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $6.61M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $586.8K | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | $102.5K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($423.1K) | Mar 29, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.60M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $3.60M | Mar 24, 2026 |
| FY2025 | Dec 31, 2023 | $3.60M | Mar 24, 2026 |
| FY2024 | Dec 31, 2022 | $3.60M | Mar 25, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($75.30M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($37.78M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($28.04M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($23.39M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($15.24M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($7.03M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.68M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $138.3K | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | ($46.87M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($47.20M) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.58M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $15.88M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $5.15M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $8.96M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $18.65M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $455.4K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $6.61M | Mar 30, 2021 |
| FY2020 | Dec 31, 2018 | $176.4K | Mar 30, 2021 |
| FY2018 | Dec 31, 2017 | $463.2K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $833.5K | Mar 29, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.97M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $30.69M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $9.69M | Mar 25, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 20, 2023 |
| FY2020 | Dec 31, 2020 | 0 | Mar 30, 2021 |
| FY2020 | Dec 31, 2019 | (1) | Mar 30, 2021 |
| FY2018 | Dec 31, 2018 | 0 | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 29, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 25, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 30, 2021 |
| FY2020 | Dec 31, 2019 | (1) | Mar 30, 2021 |
| FY2018 | Dec 31, 2018 | 0 | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 29, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8.95M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | 8.75M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | 8.54M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 8.30M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 7.68M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | 6.30M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 3.57M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 26, 2020 |
| FY2018 | Dec 31, 2017 | 113.42M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 109.69M | Mar 29, 2018 |